Skip to content
Erudio Health
menu
Erudio Healtherudio.com
Reports + MCP · for Medical information and field medical teams

The evidence and implementation questions clinicians raise about using a treatment.

Clinicians say in public which evidence and practical steps they need before they can use a treatment. Medical information and field medical can prepare balanced, sourced answers to those questions.

When you need it
  • New data, a label change or a guideline update
  • Recurring medical information enquiries on the same topic
  • Preparing field medical for scientific exchange
Ask your agent

“Before the Phase 3 reads out, what practical barriers do clinicians describe for using I-DXd in relapsed small cell lung cancer: pulmonary work-up, performance status, access after the withdrawal, where it would fit after tarlatamab? Quote the conditions they attach.”

A single report

1 report

Same prompt, two products

1 report

Practical barriers clinicians describeIDeate-Lung01 · 24 sources

Practical barriers to I-DXd in relapsed SCLC before the Phase 3 readout

The I-DXd application was withdrawn on September 25, 2026. Every statement below that assumes I-DXd would be approved, available or used is marked as having preceded the withdrawal.

Pulmonary work-up and ILD risk

  • What to look for before treating. In a video from September 10, 2026, which preceded the withdrawal, a physician (Speaker A) said patients considered for these drugs should be checked for underlying pneumonitis or pulmonary limitation: "do they have underlying evidence of pneumonitis or pulmonary limitation? I wouldn't necessarily not treat a …" Their condition: poor pulmonary function alone would not necessarily lead them to withhold treatment, since most SCLC patients would not have great PFTs. Where increased risk was suspected, they would be particularly cautious and monitor closely1.
  • Risk features. In the same video, Speaker A said underlying causes of pneumonitis, such as disease-related COPD, and a predisposition to inflammatory reactions might be linked to higher ILD risk. They called prior checkpoint-inhibitor pneumonitis a higher-risk feature. They said substantial chest radiation almost certainly raised risk, possibly because reduced pulmonary reserve could make a small amount of inflammation matter more2. The report cautions that proposed risk factors are not validated prediction rules.
  • Prior immunotherapy. In the same video, a physician (Speaker B) noted that most ES-SCLC patients get immunotherapy first-line. They asked whether nearly all patients in the I-DXd study had prior immunotherapy exposure, and said that would make the issue difficult to sort out34. Speaker A confirmed that nearly all study patients had prior immunotherapy exposure5.
  • Selection and screening. In a podcast episode from June 8, 2026, which preceded the withdrawal, a physician (Speaker C) made three points:
    • ILD is a concern that calls for patient selection and active management protocols for early recognition, intervention, stopping the drug or reducing the dose6.
    • Additional screening protocols were in place for patients who might be candidates for I-DXd7.
    • Clinicians might redirect patients at high risk for ILD to other agents in the same line and setting, and that would be important8.
  • Warning signs. In a video from April 24, 2025, which preceded the withdrawal, a medical oncologist (Speaker D) said anyone treating patients with ADCs should watch for possible ILD. They named new cough, shortness of breath or hypoxia as red flags9.

Performance status and candidacy

  • Trial eligibility. In the April 24, 2025 video, Speaker C said IDeate-Lung01 required ECOG performance status 0–1, at least one prior platinum-based line and no more than three prior lines. Patients with asymptomatic brain metastases, treated or untreated, were allowed10. The report notes that broader case discussions do not expand trial eligibility.
  • Performance status as a condition. In the September 10, 2026 video, which preceded the withdrawal, Speaker A discussed a case. They said that if the patient was willing, they might keep tarlatamab at 1 mg/kg. They said an ADC could be appropriate later if performance status allowed, but these drugs were not approved or prescribable at the time; if an opportunity arose, an ADC would be on their list of options1112.
  • Would this patient have qualified? In the same video, Speaker B asked whether a patient like the one in the case, whose blood counts and marrow seemed fine despite progression, would have been the type to go on IDeate-Lung011314. The report notes that individual cases are not general eligibility guidance.

Access around and after the withdrawal

  • Before the withdrawal.
    • In an X post from September 13, 2026, a medical oncologist (Speaker E) said I-DXd might become available very soon15.
    • An X post from an oncology show's account, September 15, 2026, laid out a sequence: chemotherapy plus immunotherapy, then immunotherapy plus tarlatamab, then ADCs such as I-DXd in second line. It expected these ADCs to become available soon16.
    • The report cautions that access expectations from before the withdrawal reports should not be treated as still operative.
  • At the withdrawal.
    • In an X post from September 25, 2026, a medical oncologist (Speaker F) reported that the company "has WITHDRAWN their application from the FDA for accelerated approval today. The company expressed concerns …" By their account, the company's concern was that I-DXd might not have been approved on Phase 2 findings alone17.
    • Speaker F also said the news made things especially challenging for patients who need options for relapsed SCLC after tarlatamab, because lurbinectedin was also being revoked. They said they remained hopeful about future Phase 3 I-DXd data18, and that trials should be discussed with patients at every major treatment decision19.
    • In the same thread, active on September 26, 2026, a medical oncologist (Speaker G) called the news precipitous. They said SCLC was a deceptively difficult setting in which to secure approval20.
    • In a thread active on September 25, 2026, a medical oncologist (Speaker H) asked whether ILD was an issue in the withdrawal21. The report cautions that an ILD contribution was questioned, not established.
  • Latest status statement among those cited here. In an X post from September 27, 2026, an X account (Speaker I) said a larger chemotherapy-controlled late-stage trial was nearly fully enrolled and the partners planned to refile when those data were available. The source does not establish Speaker I's clinical role36. The report notes that the future filing is described as planned, not completed.

Where it would fit after tarlatamab

  • Recurrent disease after a T-cell engager. In the September 10, 2026 video, which preceded the withdrawal, Speaker A said: "The initial indication for these drugs is very likely to be recurrent disease setting." They expected ADCs to be sequenced after tarlatamab, in patients previously treated with chemoimmunotherapy and a T-cell engager. They said the initial indications might be exciting, but the data would need to be awaited22.
  • Moving earlier. Speaker A also said ADC developers were trying to move ADCs earlier, to see whether very active agents in third line could replace some of the chemotherapy currently used. They said the trials' results remained to be seen2324.
  • If tarlatamab moves into maintenance. In the June 8, 2026 podcast episode, which preceded the withdrawal, Speaker C said these ADCs "they'll certainly come into the second-line setting I think especially if tarlatamab moves into maintenance which …"25.
  • If ADCs pass Phase 3. In the September 10, 2026 video, Speaker B asked how ADCs might be integrated if they passed phase 3 testing2627.
  • What to do after tarlatamab. In an X post from August 5, 2026, which preceded the withdrawal, a physician (Speaker J) wrote: "Very eagerly awaiting the ADCs: I-DXd (B7-H3), DLL3- and SEZ6-directed agents." They asked what to do after tarlatamab, or when a clinical trial or tarlatamab is unavailable or infeasible, and whether payers would cover off-label lurbinectedin28.
  • A post-withdrawal scenario. In an X post from October 7, 2026, an X account (Speaker K) proposed a conditional scenario. If tarlatamab moves into first-line maintenance, more patients would reach second line already treated with it. For that population, the benchmark for later ADC filings could fall back toward chemotherapy, potentially reopening an accelerated-approval route. Speaker K stressed that this applied only to patients who had already received tarlatamab. The source does not establish Speaker K's clinical role37.

The report cautions that forecast sequences depend on prior tarlatamab exposure, future study results and feasible access.

Bottom line

  • Pulmonary.
    • Speaker A would look for underlying pneumonitis or pulmonary limitation but would not necessarily withhold treatment for poor pulmonary function alone. They would be particularly cautious, with close monitoring, when increased risk was suspected. This preceded the withdrawal29.
    • Speaker C said clinicians might redirect high-ILD-risk patients to other agents in the same line, which also preceded the withdrawal30.
  • Performance status. Speaker A said an ADC could be appropriate later if performance status allowed, while noting the drugs were not approved at the time; this preceded the withdrawal31.
  • Access. Speaker F tied the withdrawal to a harder situation for patients after tarlatamab, with lurbinectedin also being revoked32. Speaker I reported a planned refiling once late-stage data become available33.
  • Sequence. Speaker A expected initial use in recurrent disease after tarlatamab, pending data34. Speaker C expected these ADCs to enter second line, especially if tarlatamab moves into maintenance35. Both statements preceded the withdrawal.

Sources: the numbered marks are the 24 sources the agent cited. They are not linked on this site, which names no clinician or outlet. In the report, every statement links to its source: the post, the episode at its timestamp, the abstract. Get the report free to check them.

Examples come from Erudio's free public report on IDeate-Lung01, read from the point of view of a US Medical Affairs team that owns the trial. The trial's sponsor is not an Erudio customer and did not take part. On this site the answers name no clinician, podcast or channel: the agent was told to describe people by role and sources by type, and its sources are numbered, not linked. The report itself names and links every one.
More to ask
  • “Which pulmonary tests or referral steps do clinicians say would have to be in place before treatment?”
  • “What ILD-management questions should our medical information team prepare for?”
  • “Since the filing was withdrawn, have access concerns grown or faded? Show the dated sources.”
What it does not do
  • Implementation concerns are reported as clinicians state them, not as market research.
  • No promotional messaging or claims about your product.
  • Patient statements are never presented as HCP views.
Before and after

How the work changes

Today
  • Hear implementation questions only when they reach medical information
  • Mix views of the evidence and delivery questions in one summary
  • Miss the testing, monitoring and referral steps clinicians describe in detail
With Erudio
  • Barriers separated from views of the efficacy data
  • Every concern linked to who raised it and when
  • A signal you can follow over time, not a one-off survey
What you get
  • The practical barriers clinicians name: testing, access, toxicity, monitoring
  • Which concerns are about the evidence and which are about delivery
  • Questions field medical will hear in the first months
Tools your agent calls
mcp
search_reports({ "drug": "<drug>" })
read_report({ "report_id": "<id>", "sections": ["findings"] })
search({ "query": "<drug> access reimbursement toxicity", "published_after": "<date>" })
In the report
IDeate-Lung01

NCT05280470

In IDeate-Lung01, clinicians tie use to ILD selection and monitoring, prior tarlatamab and access, and real-world eligibility, not only to response.

  1. F2
    3 of the 24 cited clinicians discuss the need for randomized evidence; accounts debate the trial's regulatory status and conditional paths to future approval
  2. F5
    Speakers make future ADC choice contingent on access, comparative evidence and pulmonary safety
  3. F8
    4 of the 24 cited clinicians discuss unmet needs in relapsed SCLC and recommend early, repeated trial discussions and enrollment when feasible

Read the findings →

Try it on your own trials

Bring the questions your team asks before its next meetings, and judge the answers against the linked sources.

Enterprise MCPRequest a pilot
Other use cases
Analysis of public HCP commentary. Not medical advice and not for promotional use. Reports do not judge efficacy, estimate consensus or promote any product.
Erudio Health Inc. · erudio.com · hello@erudio.com